Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3829607 | 0.94 | HDAC1 (0.38) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL1482181 | 0.92 | ROCK2 (0.31) | ROCK1ROCK2 | |
| SCHEMBL3834334 | 0.90 | HDAC1 (0.43) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL10476401 | 0.88 | HDAC1 (0.33) | HDAC1HDAC6 | |
| SCHEMBL11898574 | 0.88 | TSHR (0.36) | ROCK2 | |
| SCHEMBL3227901 | 0.87 | ROCK1 (0.34) | HDAC1HDAC6ROCK1ROCK2 | |
| SCHEMBL3835238 | 0.86 | HDAC1 (0.35) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL3232709 | 0.86 | HDAC1 (0.35) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL3830936 | 0.85 | HDAC1 (0.38) | HDAC1HDAC6HDAC3HDAC2NCOR2 | |
| SCHEMBL3832864 | 0.85 | HDAC1 (0.37) | HDAC1HDAC6HDAC3HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-08-09 | — | — | US | disclosed |
| EP-2292611-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | Santen Pharmaceutical Co., Ltd (JP) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202808-A1 | NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE | CBR1, NAT1, PRMT1 | HDAC1 893/4885HDAC6 3122/4885HDAC3 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.